Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aclaris Therapeutics (ACRS) Revenue (2017 - 2025)

Aclaris Therapeutics has reported Revenue over the past 9 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Revenue at $1.3 million for Q4 2025, down 85.94% from a year ago — trailing twelve months through Dec 2025 was $7.8 million (down 58.2% YoY), and the annual figure for FY2025 was $7.8 million, down 58.19%.
  • Revenue for Q4 2025 was $1.3 million at Aclaris Therapeutics, down from $3.3 million in the prior quarter.
  • Over the last five years, Revenue for ACRS hit a ceiling of $19.0 million in Q3 2022 and a floor of $1.3 million in Q4 2025.
  • Median Revenue over the past 5 years was $2.1 million (2023), compared with a mean of $4.7 million.
  • Biggest five-year swings in Revenue: surged 1046.35% in 2022 and later plummeted 85.94% in 2025.
  • Aclaris Therapeutics' Revenue stood at $1.5 million in 2021, then surged by 416.52% to $7.8 million in 2022, then soared by 126.62% to $17.6 million in 2023, then crashed by 47.58% to $9.2 million in 2024, then plummeted by 85.94% to $1.3 million in 2025.
  • The last three reported values for Revenue were $1.3 million (Q4 2025), $3.3 million (Q3 2025), and $1.8 million (Q2 2025) per Business Quant data.